Editor Profile

Joel Yager, MD

Associate Editor

About the NEJM Journal Watch Psychiatry Board

Joel Yager, MD, is Professor, Department of Psychiatry, School of Medicine, University of Colorado. He also holds Emeritus Professor positions in the Department of Psychiatry at the University of New Mexico School of Medicine and in the Department of Psychiatry and Biobehavioral Sciences at the David Geffen School of Medicine at UCLA. Dr. Yager's clinical and research interests include eating disorders, psychiatric education, health services, and other aspects of general psychiatry. He has received the Goldberger Award in Clinical Nutrition from the American Medical Association, the Vestermark Award for Excellence in Psychiatric Education from the American Psychiatric Association and the NIMH, and the Distinguished Service Award from the Academy for Eating Disorders. Dr. Yager has been writing for NEJM Journal Watch Psychiatry since its inception in 1995.

Disclosures

Editorial boards

Bulletin of the Menninger Clinic; Eating Disorders Review; International Journal of Eating Disorders; UpToDate; FOCUS: The Journal of Lifelong Learning in Psychiatry

Summaries by Joel Yager

  • April 24, 2017

    A Novel Neurofeedback Intervention for Depression

    1. Joel Yager, MD

    Real-time neurofeedback that used functional magnetic resonance imaging and increased amygdala blood-flow associated with positive memories reduced symptoms in moderately depressed patients.

  • April 20, 2017

    Do Antidepressants Contribute to the Risk for Dementia?

    1. Joel Yager, MD

    In a large Taiwanese registry study, antidepressants taken for any reason were variably associated with increased dementia risk.

  • April 6, 2017

    Completed Suicide After Self-Harm

    1. Joel Yager, MD

    After treatment for self-harm, 20% of people harm themselves again, and nearly 0.5% die by suicide within a year.

  • April 3, 2017

    Predicting Responses to Treatment for Depression

    1. Joel Yager, MD

    Brain connectivity patterns might differentiate likely response to medication or cognitive-behavioral therapy for depression, but patient preference does not.

  • March 24, 2017

    A New Medication for Tardive Dyskinesia

    1. Joel Yager, MD

    Valbenazine, a vesicular monoamine transporter 2 inhibitor, had a favorable benefit vs. harm profile for reducing tardive dyskinesia.

  • March 20, 2017

    Does Participation in Social Protest Lead to Depression?

    1. Joel Yager, MD

    Although most participants in the Hong Kong Occupy/Umbrella protest movement showed no subsequent psychological distress, a few suffered persistent, moderate depressive symptoms.

Pages